Amarin Corporation Plc's (NASDAQ:AMRN) Intrinsic Value Is Potentially 29% Above Its Share Price
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
Sector Update: Health Care Stocks Edge Lower Premarket Thursday
Amarin Says Vazkepa Secures National Reimbursement in Portugal
Express News | Amarin Shares Are Trading Higher After the Company Received National Reimbursement for VAZKEPA in Portugal
Express News | Portuguese Ministry Of Health Approves VAZKEPA For National Reimbursement To Reduce Cardiovascular Risk In High-Risk Patients; Eighth National Reimbursement In Europe; Amarin To Begin Commercialization In Portugal On August 1, 2024
Express News | Amarin Receives National Reimbursement for Vazkepa® (Icosapent Ethyl) in Portugal
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading
Sector Update: Health Care Stocks Edge Higher Premarket Monday
Amarin Commercial Partner in China Receives Regulatory Approval for Heart Drug Vascepa
Express News | Amarin's China Partner EddingPharm Receives Regulatory Approval From NMPA For VASCEPA In Mainland China For Cardiovascular Risk Reduction
Express News | Amarin Corp: Co Will Supply Product to Edding Under Negotiated Supply Terms
Express News | Amarin Corp: Edding Will Pay Co Tiered Double-Digit Percentage Royalties on Net Sales of Vascepa in China
Express News | Amarin Corp: Based Upon Nmpa Approval for Cvrr Indication, Will Earn Milestone Payment of $15 Mln
Express News | Amarin Partner Eddingpharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (Cvrr)
No Data